Cache Advisors LLC Buys New Shares in Penumbra, Inc. (NYSE:PEN)

Cache Advisors LLC acquired a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,250 shares of the company's stock, valued at approximately $534,000.

Other large investors have also made changes to their positions in the company. UMB Bank n.a. increased its holdings in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after purchasing an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new stake in Penumbra in the 4th quarter worth $56,000. Huntington National Bank grew its holdings in shares of Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after buying an additional 154 shares in the last quarter. Mather Group LLC. grew its holdings in shares of Penumbra by 208.0% during the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock worth $73,000 after buying an additional 208 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in shares of Penumbra by 25.0% during the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after buying an additional 75 shares in the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PEN shares. Wells Fargo & Company boosted their price target on shares of Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. UBS Group reaffirmed a "buy" rating and issued a $330.00 target price (up previously from $320.00) on shares of Penumbra in a research report on Thursday, April 24th. Truist Financial upped their target price on shares of Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Bank of America assumed coverage on shares of Penumbra in a research report on Friday, March 14th. They issued a "buy" rating and a $320.00 target price on the stock. Finally, Royal Bank of Canada increased their price target on shares of Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $302.40.

Penumbra Stock Up 1.4%

Shares of PEN stock traded up $3.87 during trading hours on Tuesday, reaching $272.41. 275,276 shares of the stock were exchanged, compared to its average volume of 443,318. The business's fifty day moving average is $279.45 and its two-hundred day moving average is $265.62. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $310.00. The firm has a market capitalization of $10.55 billion, a P/E ratio of 801.21, a P/E/G ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. The company had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm's revenue was up 16.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.41 earnings per share. As a group, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Activity

In other Penumbra news, CEO Adam Elsesser sold 61,600 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the transaction, the chief executive officer now owns 16,376 shares in the company, valued at approximately $4,644,069.84. The trade was a 79.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bridget O'rourke sold 100 shares of Penumbra stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $286.15, for a total value of $28,615.00. Following the completion of the sale, the director now owns 5,423 shares in the company, valued at approximately $1,551,791.45. This trade represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 176,696 shares of company stock valued at $50,207,745. 5.00% of the stock is currently owned by company insiders.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.